| P50 | author | Catherine Sautès-Fridman | Q40020459 |
| | Wolf Hervé Fridman | Q40876588 |
| | Sylvain Fisson | Q56986088 |
| P2093 | author name string | Hanane Ouakrim | |
| | Lucile Crozet | |
| | Sabrina Donnou | |
| | Aouni Mahjoub | |
| | Jérémie Cosette | |
| | Rym Ben Abdelwahed | |
| P2860 | cites work | Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization | Q24655648 |
| | Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide | Q28509007 |
| | Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells | Q33931707 |
| | Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment | Q33946604 |
| | The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides | Q34064331 |
| | CpG motifs in bacterial DNA trigger direct B-cell activation | Q34307394 |
| | Murine models of B-cell lymphomas: promising tools for designing cancer therapies | Q35779492 |
| | Toll-like receptor 9 (TLR9) agonists in the treatment of cancer | Q37050998 |
| | T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy | Q37157984 |
| | CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. | Q37376980 |
| | Important aspects of Toll-like receptors, ligands and their signaling pathways | Q37769153 |
| | TLR based therapeutics | Q37866497 |
| | Mechanism and function of a newly identified CpG DNA motif in human primary B cells | Q38316819 |
| | CpG oligodeoxynucleotides as immunotherapy in cancer. | Q38570179 |
| | Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs | Q40830636 |
| | Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. | Q44052611 |
| | What is immune privilege (not)? | Q48356667 |
| | Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself | Q80736139 |
| | B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides | Q81474815 |
| P304 | page(s) | 18 | |
| P577 | publication date | 2013-04-05 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment | |
| P478 | volume | 32 | |